Please read and agree to the terms and conditions of this site.
@WIRED 1 year ago
With new discussions around appetite-inhibitor medicines like Ozempic, it’s an interesting time to be the new CEO of WW, a service that, despite its millions of satisfied subscribers, has hoards of critics calling its points-based system the epitome of unhealthy diet culture. 6/8 https://t.co/fYX7GVIBwy
@WIRED 1 year ago
With new discussions around appetite-inhibitor medicines like Ozempic, it’s an interesting time to be the new CEO of WW, a service that, despite its millions of satisfied subscribers, has hoards of critics calling its points-based system the epitome of unhealthy diet culture. 6/8 https://t.co/18YBq1r5gO
@techcrunch.com 2 years ago
Flagship Pioneering’s new venture is betting on tRNA to treat “thousands of diseases”
@tech.eu 3 years ago
Talking Medicines raises £1 million to gather patient sentiment for pharmaceutical companies
@xconomy.com 3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com 4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms